

ASX RELEASE

19 June 2023

Annual General Meeting to be held Thursday 24 August 2023

Amplia Therapeutics Limited (ASX: ATX) ('Amplia' or the 'Company') advises that its Annual General Meeting in respect of its financial year ended 31 March 2023 is to be held on Thursday 24 August 2023.

Details of the meeting venue and other meeting arrangements will be confirmed at a later date.

In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by the Company not later than Thursday 6 July 2023.

This ASX announcement was approved and authorised for release by the Company Secretary.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).